P2613Initial combination therapy with ambrisentan and tadalafil for pulmonary arterial hypertension: clinical effect and haemodynamic changes. A multicenter retrospective analysis
نویسندگان
چکیده
منابع مشابه
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
BACKGROUND Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce. METHODS In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, participants with World Health Organization functional class II or III symptoms of pulmonary arterial hypertension who had not pre...
متن کاملAmbrisentan therapy for pulmonary arterial hypertension.
OBJECTIVES The purpose of this study was to examine the efficacy and safety of four doses of ambrisentan, an oral endothelin type A receptor-selective antagonist, in patients with pulmonary arterial hypertension (PAH). BACKGROUND Pulmonary arterial hypertension is a life-threatening and progressive disease with limited treatment options. Endothelin is a vasoconstrictor and smooth muscle cell ...
متن کاملTadalafil therapy for pulmonary arterial hypertension.
BACKGROUND Treatment options for pulmonary arterial hypertension target the prostacyclin, endothelin, or nitric oxide pathways. Tadalafil, a phosphodiesterase type-5 inhibitor, increases cGMP, the final mediator in the nitric oxide pathway. METHODS AND RESULTS In this 16-week, double-blind, placebo-controlled study, 405 patients with pulmonary arterial hypertension (idiopathic or associated),...
متن کاملInitial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
BACKGROUND Patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), in particular systemic sclerosis (SSc), had an attenuated response compared with idiopathic PAH in most trials. Thus, there is uncertainty regarding the benefit of PAH-targeted therapy in some forms of CTD-PAH. OBJECTIVE To explore the safety and efficacy of initial combination therapy wit...
متن کاملAmbrisentan for the Treatment of Pulmonary Arterial Hypertension Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy
Nazzareno Galiè, MD; Horst Olschewski, MD; Ronald J. Oudiz, MD; Fernando Torres, MD; Adaani Frost, MD; Hossein A. Ghofrani, MD; David B. Badesch, MD; Michael D. McGoon, MD; Vallerie V. McLaughlin, MD; Ellen B. Roecker, PhD; Michael J. Gerber, MD; Christopher Dufton, PhD; Brian L. Wiens, PhD; Lewis J. Rubin, MD; for the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Pl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Heart Journal
سال: 2017
ISSN: 0195-668X,1522-9645
DOI: 10.1093/eurheartj/ehx502.p2613